Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab vs Interferon Beta-1a in RRMS with Acute Optic Neuritis
NCT00771043Phase 4Withdrawn
- Sponsor
- Biogen
- Start
- Nov 2008
- Primary completion
- Aug 2009
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, randomised, open-label trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Biogen. Primary endpoint: Changes in average RNFL thickness at 36 weeks. Planned start Nov 2008; status: withdrawn.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00771043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00771043.